¤¬¤óÂè­¶ÁêÎ×¾²»î¸³¡Ê¶»Éô¡ÝÇÙ¡¢½Ä³Ö¡Ë¤ÎÊ罸¾õ¶·£´(2010ǯ12·î24Æü¸½ºß)-Japanese Clinical Trials

rinsyo2.jpg
Clinical Trials

¤¬¤óÂè­¶ÁêÎ×¾²»î¸³¡Ê¶»Éô¡ÝÇÙ¡¢½Ä³Ö¡Ë¤ÎÊ罸¾õ¶·£´(2010ǯ12·î24Æü¸½ºß)-Japanese Clinical Trials¡¡¡¡
¡¡
2010ǯ12·î24Æü¸½ºßÊç½¸Ãæ¤Î»î¸³(recruiting)¤Ç¤¹¡£»²²Ã°åÎŵ¡´Ø¼õ¿Ç¤Ë¤è¤ê¡¢´ð½à¤òËþ¤¿¤»¤ÐÎ×¾²»î¸³¤ò¼õ¤±¤ë¤³¤È¤¬½ÐÍè¤Þ¤¹¡£¾ÜºÙ¤Ï°Ê²¼¤Ç¤´³Îǧ¤¯¤À¤µ¤¤¡£(¤¬¤ó¾ðÊ󥵡¼¥Ó¥¹¤è¤êÈ´¿è)
http://ganjoho.ncc.go.jp/professional/med_info/clinical_trial/ct0032_p2.html#tabletop

•Î×¾²»î¸³¡Ê¼£¸³¡Ë¤È¤Ï²¿¤«¤òÃΤꤿ¤¤Êý¤Ø

•Î×¾²»î¸³¡Ê¼£¸³¡Ë¤Ø¤Î»²²Ã¤ò¹Í¤¨¤Æ¤¤¤ëÊý¤Ø

¢¨°Ê²¼¤Î½ç¤Ë·ÇºÜ¤¤¤¿¤·¤Þ¤¹¡£
ÂоݼÀ´µÌ¾
»î¸³Ì¾
Official scientific title of the study
»î¸³¿ÊĽ¾õ¶·
ÁÈ¿¥Ì¾
¸ø³«Æü
»î¸³ID

¢¡ÇÙ¤¬¤ó
ÇÙ¤¬¤ó¤Ø¤Î¥Ú¥×¥Á¥É¥ï¥¯¥Á¥óÎÅË¡
Peptide vaccination for lung cancer patients
°ìÈÌÊç½¸Ãæ/Open public recruiting
µ×Î±ÊÆÂç³Ø°å³ØÉôÌȱ֡¦Ìȱּ£ÎųعֺÂ
2010/01/06
UMIN000002984

¢¡È󾮺Ù˦ÇÙ´â
¿Ê¹Ô¡¦ºÆÈ¯È󾮺Ù˦ÇÙ´â¤ÎÆó¼¡¼£ÎŤˤª¤±¤ë¥Ú¥á¥È¥ì¥­¥»¥É¤È¥¨¥ë¥í¥Á¥Ë¥Ö¤ÎÊ»Íѻ¡¡Phase I/II study
A Phase I/II study of Pemetrexed plus Erlotinib therapy in Previously Treated Non-Small-Cell Lung Cancer.
°ìÈÌÊç½¸Ãæ/Open public recruiting
ÂçºåÂç³Ø°å³ØÉôÉí°É±¡¸ÆµÛ´ïÆâ²Ê
2009/12/15
UMIN000002900

¢¡ÇÙ¤¬¤ó
EBUS-TBNA/TEBUS-FNA¤Ë¤è¤ë½Ä³ÖÉ´ü¿ÇÃÇ
EBUS-TBNA and TEBUS-FNA for mediastinal staging
°ìÈÌÊç½¸Ãæ/Open public recruiting
¹ñΩɱ¡µ¡¹½ ̾¸Å²°°åÎÅ¥»¥ó¥¿¡¼
2009/12/12
UMIN000002882

¢¡È󾮺Ù˦ÇÙ´â
EGFR°äÅÁ»ÒÊѰۤòÍ­¤¹¤ëÈ󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥¨¥ë¥í¥Á¥Ë¥ÖÎÅË¡¤ÎÂèIIÁê»î¸³
Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations
°ìÈÌÊç½¸Ãæ/Open public recruiting
¹ñ²È¸øÌ³°÷¶¦ºÑÁȹçÏ¢¹ç²ñ¡¡¸×¤ÎÌçɱ¡¡¡¸ÆµÛ´ï¥»¥ó¥¿¡¼Æâ²Ê
2009/12/11
UMIN000002880

¢¡È󾮺Ù˦ÇÙ´â
EGFR°äÅÁ»ÒÊѰۤòÍ­¤¹¤ëÈ󾮺Ù˦ÇÙ´âǾž°Ü¾ÉÎã¤ËÂФ¹¤ë¥¨¥ë¥í¥Á¥Ë¥Ö¤ÎÍ­¸úÀ­¤È°ÂÁ´À­¤Î¸¡Æ¤¡¡-ÂèIIÁê»î¸³-
A phase II study of erlotinib for patients with pretreated non-small cell lung cancer with brain metastasis and sensitive EGFR mutations.
°ìÈÌÊç½¸Ãæ/Open public recruiting
ÀŲ¬¸©Î©Áí¹çɱ¡¸ÆµÛ´ï¥»¥ó¥¿¡¼
2009/12/08
UMIN000002861

¢¡Ì¤¼£ÎſʹÔÀ­¾®ºÙ˦ÇÙ´â¡ÊÈó٨ʿ¾åÈé´â¡Ë¡¡IIIB¡¢IV´ü¤Þ¤¿¤Ï½Ñ¸åºÆÈ¯¾ÉÎã
̤¼£ÎſʹÔÀ­È󾮺Ù˦ÇÙ´â¡ÊÈó٨ʿ¾åÈé´â¡ËIIIB¡¢IV´ü¤Þ¤¿¤Ï½Ñ¸åºÆÈ¯¾ÉÎã¤ËÂФ¹¤ëCisplatin(CDDP)¤ÈPemetrexed(PEM)Ê»ÍѲ½³ØÎÅË¡¤ÎÂèIIÁêÎ×¾²»î¸³
A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung Cancer
¸ÂÄêÊç½¸Ãæ/Enrolling by invitation
´â¸¦Í­ÌÀɱ¡¡¡¸ÆµÛ´ï¥»¥ó¥¿¡¼¡¡¸ÆµÛ´ïÆâ²Ê
2009/12/04
UMIN000002847

¢¡ÀÚ½üÉÔǽÈ󾮺Ù˦ÇÙ´â¡ÊÈó٨ʿ¾åÈé´â¡Ë
NSCLC¤ËÂФ¹¤ëPEM/CBDCA¤Îphase II»î¸³
Phase II trial of PEM/CBDCA for NSCLC
¸ÂÄêÊç½¸Ãæ/Enrolling by invitation
Ë̳¤Æ»ÇÙ´âÎ×¾²¸¦µæ²ñ
2009/12/04
UMIN000002846

¢¡Á°²½³ØÎÅË¡Îò¤Î¤¢¤ëºÆÈ¯È󾮺Ù˦ÇÙ´â
ºÆÈ¯È󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥¨¥ë¥í¥Á¥Ë¥Ö¤Î¸ú²Ì
Clinical relevance and biomarker search of erlotinib against chemotherapy-treated recurrent non-small cell lung cancer
°ìÈÌÊç½¸Ãæ/Open public recruiting
ÀéÍÕÂç³ØÂç³Ø±¡°å³Ø¸¦µæ±¡¸ÆµÛ´ïÆâ²Ê¡¦Î×¾²¼ðáçÉô
2009/12/01
UMIN000002811

¢¡¼£ÎÅÎò¤Î¤¢¤ëEGFR°äÅÁ»Ò¤¬ÌîÀ¸·¿¤Ç̵¤Þ¤¿¤Ï·ÚµÊ±ìÎò¤ÎÈ󾮺Ù˦ÇÙ´â
ÌîÀ¸·¿EGFR¤ÎÈ󾮺Ù˦ÇÙ´â¤Ë¤ª¤±¤ë¥¨¥í¥Á¥Ë¥ÖÅêÍ¿»î¸³¤È¥Ð¥¤¥ª¥Þ¡¼¥«¡¼¸¡º÷
Erlotonib in pre-treated NSCLC with wild type EGFR
°ìÈÌÊç½¸Ãæ/Open public recruiting
ËÌÅìÆüËܸ¦µæµ¡¹½/Åìµþ¤¬¤ó²½³ØÎÅË¡¸¦µæ²ñ
2009/11/25
UMIN000002795

¢¡EGFR°äÅÁ»ÒÊѰۤ¬Â¸ºß¤¹¤ëÈ󾮺Ù˦ÇÙ´â¡ÊÈó٨ʿ¾åÈé´â¡Ë
EGFRÊѰÛÍÛÀ­¤ÎÈ󾮺Ù˦ÇÙ´â¡ÊÈó٨ʿ¾åÈé´â¡Ë¤Ë¤ª¤±¤ë¥²¥Õ¥£¥Á¥Ë¥ÖÏ¢ÆüÅêÍ¿/²½³ØÎÅË¡¤È¸òÂåÅêÍ¿¤ÎÈæ³Ó»î¸³
Continuous gefitinib plus chemotherapy versus alternation of gefitinib and chemotherapy in NSCLC with EGFR mutations
°ìÈÌÊç½¸Ãæ/Open public recruiting
ËÌÅìÆüËܸ¦µæµ¡¹½/Åìµþ¤¬¤ó²½³ØÎÅË¡¸¦µæ²ñ
2009/11/20
UMIN000002789

¢¡¼£ÎÅÄñ¹³À­¾®ºÙ˦ÇÙ´â
¼£ÎÅÄñ¹³À­¾®ºÙ˦ÇÙ´â¤ËÂФ¹¤ë±ö»À¥¢¥à¥ë¥Ó¥·¥óÎÅË¡¤ÎÂèIIÁê»î¸³ (JCOG0901)
Phase II study of Amrubicin in patients with Small-Cell Lung Cancer that is refractory or relapsed within 90 days of completing previous treatment (JCOG0901)
°ìÈÌÊç½¸Ãæ/Open public recruiting
ÆüËÜÎ×¾²¼ðá縦µæ¥°¥ë¡¼¥×¡ÊJCOG¡Ë
2009/11/13
UMIN000002763

¢¡È󾮺Ù˦ÇÙ´â
²½³ØÎÅË¡´û¼£Îſʹԡ¦ºÆÈ¯È󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥¨¥ë¥í¥Á¥Ë¥Ö¤ÎÍ­¸úÀ­¤È°ÂÁ´À­¤Î¸¡Æ¤¡¡¡ÝÂèIIÁê»î¸³-
A Phase II Study of Erlotinib for previously treated Non-Small Cell Lung Cancer Patients
°ìÈÌÊç½¸Ãæ/Open public recruiting
¹âÃÎÂç³Ø°å³ØÉô¡¡·ì±Õ¡¦¸ÆµÛ´ïÆâ²Ê
2009/11/11
UMIN000002735

¢¡Ì¤¼£ÎŤÎIIIB/IV´ü¤ÎÈó٨ʿ¾åÈéÈ󾮺Ù˦ÇÙ´â
¿Ê¹ÔÈó٨ʿ¾åÈéÈ󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥Ú¥á¥È¥ì¥­¥»¥É¡Ü¥·¥¹¥×¥é¥Á¥ó¼£ÎÅ¡ÊÆ³Æþ²½³ØÎÅË¡¡Ë¸å¥Ú¥á¥È¥ì¥­¥»¥É¤Ë¤è¤ë°Ý»ý²½³ØÎÅË¡¡Ê¥á¥ó¥Æ¥Ê¥ó¥¹¡Ë¤ÎÍ­¸úÀ­¤ª¤è¤Ó°ÂÁ´À­¤ò¸¡Æ¤¤¹¤ëÂèIIÁêÎ×¾²»î¸³
A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer.
°ìÈÌÊç½¸Ãæ/Open public recruiting
ÆÈΩ¹ÔÀ¯Ë¡¿Í¹ñΩɱ¡µ¡¹½¶áµ¦Ãæ±û¶»Éô¼À´µ¥»¥ó¥¿¡¼
2009/11/02
UMIN000002686

¢¡È󾮺Ù˦ÇÙ´â
PS2´µ¼Ô¤ËÂФ¹¤ëpemetrexedñºÞ¤ÎphaseIIstudy
Pemetrexed Monotherapy for Performance Status 2 Patients
°ìÈÌÊç½¸Ãæ/Open public recruiting
¿À¸ÍÇÙ¤¬¤ó¸¦µæ²ñ
2009/10/15
UMIN000002622

¢¡´°Á´ÀÚ½ü¤µ¤ì¤¿ÉÂÍýÉ´üII-IIIA´üÈ󾮺Ù˦ÇÙ´â
È󾮺Ù˦ÇÙ´â½Ñ¸åTS-1°Ý»ýÎÅË¡¤Îfeasibility study¤È½Û´Ä¼ðáçºÙ˦(CTC)¤Î¸¡Æ¤
Feasibility study of postoperative maintenance TS-1 chemotherapy and a biomarker study of CTC in NSCLC
¸ÂÄêÊç½¸Ãæ/Enrolling by invitation
ʼ¸Ë°å²ÊÂç³Ø¸ÆµÛ´ï³°²Ê
2009/10/07
UMIN000002592

¢¡È󾮺Ù˦ÇÙ¤¬¤ó
ºÆÈ¯È󾮺Ù˦ÇÙ¤¬¤ó¤ËÂФ¹¤ë¥¢¥à¥ë¥Ó¥·¥óËè½µÅêͿˡ¤ÎÂ裲Áê»î¸³
Phase II study of weekly amrubicin for non-small cell lung cancer patients
°ìÈÌÊç½¸Ãæ/Open public recruiting
¹ñΩɱ¡µ¡¹½Ì¾¸Å²°°åÎÅ¥»¥ó¥¿¡¼
2009/10/01
UMIN000002570

¢¡°­À­ÇÙ¼ðáç
Switching controller¤òÍѤ¤¤¿ÇÙ¼ðáç¤ËÂФ¹¤ëRFA RFA using a switching controller for lung neopasms
°ìÈÌÊç½¸Ãæ/Open public recruiting
»°½ÅÂç³Ø°å³ØÉôÉí°É±¡IVR²Ê
2009/09/16
UMIN000002504
´ØÏ¢µ­»ö


¥³¥á¥ó¥È
¥³¥á¥ó¥È¤ÎÅê¹Æ


´ÉÍý¼Ô¤Ë¤À¤±É½¼¨¤òµö²Ä¤¹¤ë

¥È¥é¥Ã¥¯¥Ð¥Ã¥¯
http://paxxmedia.blog38.fc2.com/tb.php/664-39ed8436
¤³¤Îµ­»ö¤Ë¥È¥é¥Ã¥¯¥Ð¥Ã¥¯¤¹¤ë(FC2¥Ö¥í¥°¥æ¡¼¥¶¡¼)